1259P Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)

Abstract

Tx options for METex14 NSCLC have been limited to chemotherapy (Ctx), immunotherapy (IO) and multikinase inhibitors (MKi) until the FDA approvals of selective MET inhibitors (METi) from 2020. Timing of NGS testing in relation to systemic first-line Tx (1L) initiation and Tx selection patterns for METex14 NSCLC pts in the real-world prior to those approvals warrants evaluation to guide future practice.